Prophylaxis of typhoid fever Infections and Infestations Typhoid and paratyphoid fevers
Conditions
Interventions
Biological:
Group A: Three oral doses of Vivotif®
administered with an interval of 1 day
Group B: one intramuscular dose of Typherix®
will be administered
Total duration of follow-up: approximately four weeks
Sponsors
Helsinki University Central Hospital (Finland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female subjects aged 18 to 65 years 2. Free of obvious health problems 3. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Vaccination against typhoid fever within 5 years before dosing 2. History of clinical typhoid fever, clinical paratyphoid A or B fever 3. Current intake of antibiotics or end of antibiotic therapy less than 8 days before first investigative medicinal product (IMP) administration 4. Standard exclusion criteria (allergic to vaccine components, acute disease, immunosuppressed, serious chronic illness, pregancy or lactation, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of specific IgA- IgG- and IgM-secreting antibody cells in peripheral blood using ELISPOT, measured at day 7. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the expression of various homing receptors on antigen-specific antibody-secreting cells by separating the PBMCs with immunomagnetic cell sorting according to their HR expressions and by investigating specific ASC in the resulting subpopulations 2. Antibody analyses from serum (Widal test/ELISA) 3. Cell-mediated immune response Measured at week 1 and 4. | — |
Countries
Finland
Outcome results
None listed